Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial.Heikki Joensuu, for The Finnish Breast Cancer Group, James D. Ahlgren et al.|Cancer Research|2009Cited by 8
Abstract PD01-02: Integration of Capecitabine into Anthracycline-and Taxane-Based Adjuvant Therapy for Triple-Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX StudyHenrik Lindman, Heikki Joensuu, P-L Kellokumpu-Lehtinen et al.|Cancer Research|2010Cited by 6
Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).Heikki Joensuu, Henrik Lindman, Päivi Auvinen et al.|Journal of Clinical Oncology|2010Cited by 6